India's Proposed Tweak Of New Drug Rules: Bridge To Data Exclusivity?
Executive Summary
A key Indian advisory panel is expected to consider a crucial tweak to certain regulations pertaining to the approval of “new drugs”, which domestic firms allege could facilitate a different form of data exclusivity and also limit competition.
You may also be interested in...
Does India's Perpetual Licensing Plan Risk Backfiring?
India's wide-ranging drug regulation overhaul plan, including a perpetual licensing system aimed at simplifying processes and potentially delinking licensing and enforcement responsibilities may well emerge as a double-edged sword.
More Pressure On Pharma: UN Report Backs Compulsory Licensing
Heavy-weight United Nations panel makes tough recommendations favoring compulsory licensing – an issue that has riled Big Pharma but has at least one industry proponent, Cipla's chair Yusuf Hamied, who talked to the Pink Sheet about the "excesses" of intellectual property rights.
India IPR Realities: Pharma, Legal Heads Discuss Winds Of Change, ‘Damocles Sword’
Leaders from Novartis, Bayer, Sun Pharma, the Indian Pharmaceutical Alliance, Médecins Sans Frontières and Anand and Anand discuss India’s evolving intellectual property rights landscape, including pre-grant oppositions, enforcement action and other realities. Concerns around evergreening, restrictions on patent-eligible subject matter and compulsory licensing were also key talking points at a recent conference in Hyderabad.